OnKure Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
(in thousands, except share information)
| Additional · Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Preferred Stock · Class A Common stock · Class B Common stock · Paid-In · Accumulated · Stockholders' | ||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Equity (Deficit) | ||||||||||
| Balance, December 31, 2023 | 6,840,620 | $129,825 | 313,747 | $— | — | $— | $209 | $(102,051) | $(101,842) | |
| Issuance of Class A Common Stock for cash upon the exercise of stock options | — | — | 1,002 | — | — | — | 10 | — | 10 | |
| Share-based compensation expense | — | — | — | — | — | — | 107 | — | 107 | |
| Net loss | — | — | — | — | — | — | — | (9,536) | (9,536) | |
| Balance, March 31, 2024 | 6,840,620 | 129,825 | 314,749 | — | — | — | 326 | (111,587) | (111,261) | |
| Issuance of Class A Common Stock for cash upon the exercise of stock options | — | — | 1,130 | — | — | — | 10 | — | 10 | |
| Share-based compensation | — | — | — | — | — | — | 1,813 | — | 1,813 | |
| Net loss | — | — | — | — | — | — | — | (14,139) | (14,139) | |
| Balance, June 30, 2024 | 6,840,620 | 129,825 | 315,879 | — | — | — | 2,149 | (125,726) | (123,577) | |
| Issuance of Class A Common Stock for cash upon the exercise of stock options | — | — | 344 | — | — | — | 6 | — | 6 | |
| Share-based compensation | — | — | — | — | — | — | 77 | — | 77 | |
| Net loss | — | — | — | — | — | — | — | (11,556) | (11,556) | |
| Balance, September 30, 2024 | 6,840,620 | 129,825 | 316,223 | — | — | — | 2,232 | (137,282) | (135,050) | |
| Conversion of Convertible Preferred Stock for Class A and B Common Stock in connection with the Merger | (6,840,620) | (129,825) | 6,154,093 | 1 | 686,527 | — | 129,824 | — | 129,825 | |
| Issuance of Class A Common Stock in the Concurrent Financing, less issuance costs | — | — | 2,571,736 | — | — | — | 54,428 | — | 54,428 | |
| Issuance of common stock to former stockholders of Reneo Pharmaceuticals, Inc. in the reverse recapitalization | — | — | 3,343,604 | — | — | — | 65,499 | — | 65,499 | |
| Reverse recapitalization transaction costs of OnKure | — | — | — | — | — | — | (2,085) | — | (2,085) | |
| Issuance of Class A Common Stock for the conversion of Convertible Promissory Notes | — | — | 267,269 | 6,120 | 6,120 | |||||
| Issuance of Class A common stock for the settlement of restricted stock units | — | — | 7,700 | — | — | — | — | — | — | |
| Adjustment for fractional shares in the reverse recapitalization | — | — | (35) | — | — | — | — | — | — | |
| Share-based compensation | — | — | — | — | — | — | 2,533 | — | 2,533 | |
| Net loss | — | — | — | — | — | — | — | (17,442) | (17,442) | |
| Balance, December 31, 2024 | — | $— | 12,660,590 | $1 | 686,527 | $— | $258,551 | $(154,724) | $103,828 | |
| Vesting of restricted stock units, net | — | — | 94,758 | — | — | — | — | — | — | |
| Share-based compensation | — | — | — | — | — | — | 2,745 | — | 2,745 | |
| Net loss | — | — | — | — | — | — | — | (15,925) | (15,925) | |
| Balance, March 31, 2025 | — | — | 12,755,348 | 1 | 686,527 | — | 261,296 | (170,649) | 90,648 | |
| Vesting of restricted stock units | — | — | 88,086 | — | — | — | — | — | — | |
| Share-based compensation | — | — | — | — | — | — | 2,908 | — | 2,908 | |
| Net loss | — | — | — | — | — | — | — | (15,390) | (15,390) | |
| Balance, June 30, 2025 | — | $— | 12,843,434 | $1 | 686,527 | $— | $264,204 | $(186,039) | $78,166 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.